Envista Closes Divestiture of KaVo Treatment Unit & Instrument Business

Rhea-AI Summary

Envista Holdings Corporation (NYSE: NVST) has successfully completed the sale of its KaVo Treatment Unit & Instrument business, receiving $317.3 million in cash upon closing. The total gross proceeds from the divestiture are projected to reach $383 million, which includes earnouts to be received by mid-2022. This strategic move allows Envista to allocate funds towards acquisitions and internal investments, enhancing its offerings to dental professionals. The Imaging business under the KaVo brand will remain with Envista.

Positive

• Received $317.3 million in cash from the divestiture.
• Total gross proceeds projected at $383 million, providing capital for strategic acquisitions and investments.

Negative

• None.

BREA, Calif., Jan. 3, 2022 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that it closed the previously disclosed divestiture of its KaVo Treatment Unit & Instrument business. Envista received $317.3 million in cash on the closing date and expects to receive total gross proceeds of $383 million, which includes an earnout and certain adjustments to be paid out by the first half of 2022. Envista will use the proceeds to fund strategic acquisitions and internal investments.

Envista Holdings Corporation CEO Amir Aghdaei said, "Envista is focused on its strategic priorities to build and optimize a more consumables and digitally enabled, workflow-oriented portfolio. This divestiture further enables Envista to invest organically and inorganically, expand our product offerings, and realize our purpose of partnering with dental professionals to improve patients' lives by digitizing, personalizing, and democratizing dental care."

The business sold was part of Envista's Equipment & Consumables segment. Envista's Imaging business, which also currently uses the KaVo brand for select products, will stay with Envista as part of the Equipment & Consumables segment. 

Additional details about the transaction will be set forth in a Current Report on Form 8-K to be filed by Envista and available at www.sec.gov.

ABOUT ENVISTA

Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Our comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers an estimated 90% of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments, and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the effect of the announcement of the transaction on the Company's business relationships, operating results, share price or business generally, the outcome of any legal proceedings that may be instituted against the Company related to the transaction, the failure to realize the expected benefits resulting from the transaction, the impact of the COVID-19 pandemic, including new variants of the virus, the pace of recovery in the markets in which we operate, global supply chain disruptions and potential staffing shortages, the conditions in the U.S. and global economy, the markets served by us and the financial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations, contractions or growth rates and cyclicality of markets we serve, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, significant restrictions and/or potential liability based on tax implications of transactions with Danaher, security breaches or other disruptions of our information technology systems or violations of data privacy laws, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, the impact of regulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors, and disruptions relating to war, terrorism, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2020 and our Quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

CONTACT
Stephen Keller
Investor Relations
Envista Holdings Corporation
200 S. Kraemer Blvd., Building E
Brea, CA 92821
Telephone: (714) 817-7000
Fax: (714) 817-5450       

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/envista-closes-divestiture-of-kavo-treatment-unit--instrument-business-301452515.html

SOURCE Envista Holdings Corporation

FAQ

What is the significance of the NVST divestiture announcement?

The divestiture allows Envista to strengthen its focus on strategic investments and acquisitions.

How much did Envista receive from the KaVo business sale?

Envista received $317.3 million in cash upon closing the sale.

What are the total expected proceeds from the KaVo divestiture?

The total expected proceeds from the divestiture are $383 million.

Will any parts of the KaVo brand remain with Envista?

Yes, the KaVo Imaging business will stay with Envista.

When can Envista expect to receive the remainder of the divestiture proceeds?

Envista expects to receive the remainder of the proceeds by the first half of 2022.